Insulin Degludec Has Lower Hypoglycemia Risk than Insulin Glargine U100 in Older People with Type 2 Diabetes (T2D)

被引：3
|
作者：
Heller, Simon R.
Devries, J. Hans
Wysham, Carol H.
Hansen, Charlotte T.
Hansen, Melissa V.
Frier, Brian M.
机构：
来源：
DIABETES | 2018年 / 67卷
关键词：
D O I：
10.2337/db18-107-OR
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Insulin degludec U100 is associated with lower risk for severe and symptomatic hypoglycemia as compared with insulin glargine U100 in subjects with type 1 diabetes
    Tentolouris, Anastasios
    Eleftheriadou, Ioanna
    Tentolouris, Nikolaos
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (03)
  • [2] Efficacy and Safety of Insulin Degludec (IDeg) vs. Insulin Glargine U100 (IGlar) in Hispanic Patients with Type 2 Diabetes (T2D)
    Chaykin, Louis B.
    Bhargava, Anuj
    Wysham, Carol H.
    Abrahamsen, Trine
    Van Leeuwen, Michiel
    De la Rosa, Raymond
    DIABETES, 2017, 66 : A617 - A617
  • [3] Effect of insulin degludec U100 vs insulin glargine U100 on time in range in patients with type 2 diabetes at risk of hypoglycaemia
    Goldenberg, R.
    Aroda, V. R.
    Billings, L. K.
    Christiansen, A. S. L.
    Donatsky, A. M.
    Rizi, E. Parvaresh
    Podgorski, G.
    Raslova, K.
    Klonoff, D. C.
    Bergenstal, R. M.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S318 - S319
  • [4] A reduced risk of hypoglycaemia with insulin degludec vs. insulin glargine U100 in Asian insulin-naive patients with T2D
    Yang, Wenying
    Li, Qiang
    Li, Zhengfang
    Yang, Jin-Kui
    Ye, Shandong
    Hansen, Charlotte
    Xu, Hongfei
    Pan, Changyu
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S115 - S115
  • [5] Cardiovascular (CV) Safety and Severe Hypoglycemia Benefit of Insulin Degludec vs. Insulin Glargine U100 in Older Patients (=65 Years) with Type 2 Diabetes (T2D)-Observations from DEVOTE
    Pratley, Richard E.
    Emerson, Scott S.
    Franek, Edward
    Gilbert, Matthew P.
    Marso, Steven P.
    Mcguire, Darren K.
    Pieber, Thomas R.
    Poulter, Neil R.
    Hansen, Charlotte T.
    Hansen, Melissa V.
    Mark, Thomas
    Moses, Alan C.
    Zinman, Bernard
    DIABETES, 2018, 67
  • [6] Converting to Insulin Degludec/Liraglutide (IDegLira) Is Efficacious Regardless of Pretrial Insulin Dose in Patients with Type 2 Diabetes (T2D) Uncontrolled on Insulin Glargine U100 (IGlar)
    Meneghini, Luigi F.
    Jaeckel, Elmar
    Leiter, Lawrence A.
    Lingvay, Ildiko
    Harvey, John N.
    Begtrup, Kamilla
    Chandarana, Keval
    Vilsboll, Tina
    DIABETES, 2017, 66 : A289 - A289
  • [7] Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes The SWITCH 2 Randomized Clinical Trial
    Wysham, Carol
    Bhargava, Anuj
    Chaykin, Louis
    de la Rosa, Raymond
    Handelsman, Yehuda
    Troelsen, Lone N.
    Kvist, Kajsa
    Norwood, Paul
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 318 (01): : 45 - 56
  • [8] Higher derived time in range with insulin degludec/insulin aspart vs insulin glargine U100 in Japanese adults with T2D
    Philis-Tsimikas, A.
    D'Cruz, J. M.
    De Block, C.
    Hachmann-Nielsen, E.
    Sivarathinasami, R.
    Onishi, Y.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2022, 186
  • [9] Lower rates of hypoglycaemia in older individuals with type 2 diabetes using insulin degludec versus insulin glargine U100: Results from SWITCH 2
    Heller, Simon R.
    DeVries, J. Hans
    Wysham, Carol
    Hansen, Charlotte T.
    Hansen, Melissa V.
    Frier, Brian M.
    DIABETES OBESITY & METABOLISM, 2019, 21 (07): : 1634 - 1641
  • [10] Switching to Insulin Degludec from Insulin Glargine U100 Improves Glycemic Control in People with Type 1 (T1D) or Type 2 diabetes (T2D) in a Real-World Setting
    Knudsen, Soren T.
    Tentolouris, Nikolaos
    Schultes, Bernd
    Lapolla, Annunziata
    Eidenmueller, Markus
    Prager, Rudolf
    Catarig, Andrei-Mircea
    Wolden, Michael L.
    Siegmund, Thorsten
    DIABETES, 2018, 67
12345